The Clinical and Economic Value of ClearGuard HD in the Inpatient Setting for Hemodialysis Catheter Management.

This was a retrospective before-after study, not a randomized trial, so it cannot prove ClearGuard caused the reduction. There was no third site that did not use ClearGuard over July 2021 to April 2025, so other health care or environmental effects could explain the drop. CLABSI rates were not normalized to actual catheter dwell days or patient days, and the analysis assumed the same number of catheter dwell days each month. The baseline and implementation periods were different lengths, 18 months versus 28 months, which can make comparison harder. Exclusions of continuous renal replacement therapy, continuous venovenous hemodialysis, and mucosal barrier injury infections mean results may not apply to all inpatient dialysis patients. Compliance was checked by bedside audits and chart reviews, but documentation errors and observer variability may have affected measured use. Staff education and implementation varied across sites and could have influenced outcomes. Because implementation included manufacturer education, videos, competency validation, and checklist changes alongside ClearGuard, the contribution of the cap alone cannot be separated.

The manufacturer of ClearGuard, ICU Medical, funded copyediting and biostatistical analysis. The paper states the sponsor had no role in study design, data collection, or data interpretation.

Do not read the 63% reduction as proof that ClearGuard alone caused the drop. This was a retrospective before-after study with no control site, and the implementation also included manufacturer education, competency validation, and checklist changes.